Prostate cancer chemotherapy in the era of targeted therapy | Zendy

Agnieszka Michael | Zendy; Konstantinos Syrigos | Zendy; Hardev Pandha | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prostate cancer chemotherapy in the era of targeted therapy

Author(s) -

Agnieszka Michael,

Konstantinos Syrigos,

Hardev Pandha

Publication year - 2008

Publication title -

prostate cancer and prostatic diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2

H-Index - 64

eISSN - 1476-5608

pISSN - 1365-7852

DOI - 10.1038/pcan.2008.32

Subject(s) - medicine , prostate cancer , oncology , chemotherapy , cancer , prostate

Prostate cancer is the most common cancer in men accounting for around 24% of all male cancers in United Kingdom. The role of chemotherapy in the neoadjuvant and adjuvant setting is still unclear despite considerable progress in this area. Chemotherapy for advanced prostate cancer has become the standard of care, however options of treatment following taxotere failure are still limited. This review summarizes recent advances in chemotherapy treatment options for early as well as advanced prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research